Related Experiment Videos
Normal tissue effects: reporting and analysis
Soren M Bentzen1, Wolfgang Dörr, Mitchell S Anscher
1Gray Cancer Institute, Mount Vernon Hospital, Northwood, UK. bentzen@gci.ac.uk
Abstract:
Any effective cancer therapy developed to date is associated with a spectrum of normal tissue effects of varying incidence and severity. With an increasing number of novel therapeutic approaches undergoing clinical testing and an increased effort to optimize the established treatment modalities, methods for reliable quantification of normal tissue effects have become a key element in advancing cancer care. Here, we present a review of many of the issues involved in reporting and analyzing clinical normal tissue effect data. A distinction is introduced between explorative (science-driven) and pragmatic (patient-centered) studies. The desirable properties of criteria for reporting and grading toxicity are discussed from a biological and clinical perspective. Validation of toxicity criteria and the statistical issues involved in analyzing this type of data are presented with special emphasis on descriptors of the time evolution of toxicity. Finally, we discuss surrogate markers for late effects, mechanistic studies, and the design of clinical studies with normal tissue endpoints as a primary outcome. It is concluded that a consensus is required on guidelines for the reporting of normal tissue effects to improve the comparability of published reports on treatment outcome.
Insights
Quantifying normal tissue effects from cancer therapies is crucial for advancing patient care. Standardized reporting guidelines are needed to ensure comparable and reliable data on treatment outcomes.
Area of Science:
- Oncology
- Radiation Oncology
- Clinical Trials
Background:
- Cancer therapies often cause normal tissue effects, impacting patient outcomes.
- Optimizing cancer treatments requires reliable quantification of these adverse effects.
- Advancing cancer care necessitates robust methods for assessing normal tissue toxicity.
Purpose of the Study:
- To review issues in reporting and analyzing clinical normal tissue effect data.
- To discuss desirable properties of toxicity reporting and grading criteria.
- To highlight statistical considerations and study design for normal tissue endpoints.
Main Methods:
- Literature review of normal tissue effect data analysis in cancer therapy.
- Distinction between explorative and pragmatic study designs.
- Discussion of biological, clinical, and statistical perspectives on toxicity assessment.
Main Results:
- Explorative vs. pragmatic study distinctions are proposed.
- Validation of toxicity criteria and statistical analysis of time-evolution data are discussed.
- Surrogate markers for late effects and study designs with normal tissue endpoints are considered.
Conclusions:
- Consensus on guidelines for reporting normal tissue effects is essential.
- Improved comparability of treatment outcome reports is a key goal.
- Standardized reporting will enhance the reliability of cancer therapy evaluations.